These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Experimental myasthenia gravis: a model of receptor disease. Takamori M; Kasai M Int J Neurol; 1980; 14(1):47-60. PubMed ID: 6293991 [No Abstract] [Full Text] [Related]
24. Immunopathologic events at the endplate in myasthenia gravis. Ashizawa T; Appel SH Springer Semin Immunopathol; 1985; 8(3):177-96. PubMed ID: 2413561 [No Abstract] [Full Text] [Related]
25. Electrophysiological studies of thymectomized and nonthymectomized acetylcholine receptor-immunized animal models of myasthenia gravis. Niemi WD; Nastuk WL; Chang HW; Penn AS; Rosenberry TL Exp Neurol; 1979 Jan; 63(1):1-27. PubMed ID: 223859 [No Abstract] [Full Text] [Related]
26. Insights in the autoimmunity of myasthenia gravis. De Baets MH Autoimmunity; 2010 Aug; 43(5-6):341-3. PubMed ID: 20380585 [TBL] [Abstract][Full Text] [Related]
27. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation. Wilson S; Vincent A; Newsom-Davis J J Neurol Neurosurg Psychiatry; 1983 May; 46(5):377-82. PubMed ID: 6101171 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic and clinical classification of autoimmune myasthenia gravis. Berrih-Aknin S; Frenkian-Cuvelier M; Eymard B J Autoimmun; 2014; 48-49():143-8. PubMed ID: 24530233 [TBL] [Abstract][Full Text] [Related]
29. Antibody-mediated disorders of neuromuscular transmission. Vincent A Suppl Clin Neurophysiol; 2004; 57():147-58. PubMed ID: 16106615 [No Abstract] [Full Text] [Related]
30. [Physiopathology of myasthenia gravis. A review (author's transl)]. Bergmans J Ann Chir; 1980 Mar; 34(3):147-57. PubMed ID: 6245616 [No Abstract] [Full Text] [Related]
31. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; MartÃnez-MartÃnez P; De Baets MH; Losen M Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584 [TBL] [Abstract][Full Text] [Related]
34. Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules. Sterz R; Hohlfeld R; Rajki K; Kaul M; Heininger K; Peper K; Toyka KV Muscle Nerve; 1986 May; 9(4):306-12. PubMed ID: 2423869 [TBL] [Abstract][Full Text] [Related]
35. Genetic and antibody-mediated channelopathies at the neuromuscular junction. Vincent A; Mills K Electroencephalogr Clin Neurophysiol Suppl; 1999; 50():250-8. PubMed ID: 10689470 [No Abstract] [Full Text] [Related]
36. Immunology of acetylcholine receptors in relation to myasthenia gravis. Vincent A Physiol Rev; 1980 Jul; 60(3):756-824. PubMed ID: 6248907 [No Abstract] [Full Text] [Related]
37. The immunopathology of myasthenia gravis. Engel AG Int J Neurol; 1980; 14(1):35-46. PubMed ID: 6293990 [No Abstract] [Full Text] [Related]
38. [Myasthenia gravis induced by autoantibodies against MuSK]. Shigemoto K; Konishi T; Ohta M Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361 [TBL] [Abstract][Full Text] [Related]